Vrudhula; Vivekananda M.

Patent Applications and Registrations

Patent applications and USPTO patent grants for Vrudhula; Vivekananda M..The latest application filed is for "heterocyclic kinase inhibitors".

Company Profile

0.23.17

Vrudhula; Vivekananda M. - Killingworth CT
Vrudhula; Vivekananda M - Killingworth CT
Vrudhula; Vivekananda M. - Brier WA
Vrudhula; Vivekananda M. - Snohomish County WA
Vrudhula; Vivekananda M. - Edmonds WA
Vrudhula; Vivekananda M. - Mountlake Terrace WA

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Heterocyclic kinase inhibitors Grant 10,035,777 - Dzierba , et al. July 31, 2	2018-07-31
Heterocyclic Kinase Inhibitors App 20170260145 - Dzierba; Carolyn Diane ; et al.	2017-09-14
GSK-3 inhibitors Grant 9,718,804 - Luo , et al. August 1, 2	2017-08-01
Aryl amide-based kinase inhibitors Grant 9,708,337 - Vrudhula , et al. July 18, 2	2017-07-18
Aryl Lacta Kinase Inhibitors App 20160333006 - Vrudhula; Vivekananda M. ; et al.	2016-11-17
Gsk-3 Inhibitors App 20160272621 - Luo; Guanglin ; et al.	2016-09-22
Aryl Ether-base Kinase Inhibitors App 20160222021 - Vrudhula; Vivekananda M. ; et al.	2016-08-04
Aryl Amide-based Kinase Inhibitors App 20160016967 - Vrudhula; Vivekananda M. ; et al.	2016-01-21
Aryl ether-base kinase inhibitors Grant 8,969,564 - Vrudhula , et al. March 3, 2	2015-03-03
Aryl lactam kinase inhibitors Grant 8,901,305 - Vrudhula , et al. December 2, 2	2014-12-02
Aryl Ether-Base Kinase Inhibitors App 20140179725 - Vrudhula; Vivekananda M. ; et al.	2014-06-26
Aryl ether-base kinase inhibitors Grant 8,703,953 - Vrudhula , et al. April 22, 2	2014-04-22
Aryl Lactam Kinase Inhibitors App 20140038999 - Vrudhula; Vivekananda M. ; et al.	2014-02-06
Aryl Ether-Base Kinase Inhibitors App 20130237555 - Vrudhula; Vivekananda M. ; et al.	2013-09-12
Pyrazinone modulator of corticotropin-releasing factor receptor activity Grant 8,372,847 - Hartz , et al. February 12, 2	2013-02-12
Substituted heterocyclic ethers and their use in CNS disorders Grant 8,026,257 - Degnan , et al. September 27, 2	2011-09-27
Pyrazinone Modulator of Corticotropin-Releasing Factor Receptor Activity App 20110166160 - Hartz; Richard A. ; et al.	2011-07-07
(S)-4-(1-cyclopropyl-2-methoxyethyl)-6-(6-(difluoromethoxy)-2,5-dimethylpy- ridin-3-ylamino)-5-oxo-4,5-dihydropyrazine-2-carbonitrile: a pyrazinone modulator of corticotropin-releasing factor receptor activity Grant 7,932,256 - Hartz , et al. April 26, 2	2011-04-26
Pyrazinone Modulator of Corticotropin-Releasing Factor Receptor Activity App 20100029684 - Hartz; Richard A. ; et al.	2010-02-04
Pyrrolotriazine aniline prodrug compounds useful as kinase inhibitors Grant 7,572,795 - Liu , et al. August 11, 2	2009-08-11
Pyrrolotriazine Aniline Prodrug Compounds Useful As Kinase Inhibitors App 20090156555 - Liu; Chunjian ; et al.	2009-06-18
Substituted Heterocyclic Ethers and Their Use in CNS Disorders App 20090018132 - Degnan; Andrew P. ; et al.	2009-01-15
Pyrrolotriazine Aniline Prodrug Compounds Useful As Kinase Inhibitors App 20070213300 - Liu; Chunjian ; et al.	2007-09-13
Imidazolyl derivatives as corticotropin releasing factor inhibitors Grant 7,238,699 - Vrudhula , et al. July 3, 2	2007-07-03
Imidazolyl derivatives as corticotropin releasing factor inhibitors Grant 7,211,669 - Vrudhula , et al. May 1, 2	2007-05-01
Atropisomers of 3-substituted-4-arylquinolin-2-one derivatives Grant 6,939,968 - Vrudhula , et al. September 6, 2	2005-09-06
Imidazolyl derivatives as corticotropin releasing factor inhibitors Grant 6,888,004 - Dubowchik , et al. May 3, 2	2005-05-03
Imidazolyl derivatives as corticotropin releasing factor inhibitors App 20040254382 - Vrudhula, Vivekananda M. ; et al.	2004-12-16
Imidazolyl derivatives as corticotropin releasing factor inhibitors App 20040225001 - Vrudhula, Vivekananda M. ; et al.	2004-11-11
Atropisomers of 3-substituted-4-arylquinolin-2-one derivatives App 20040147749 - Vrudhula, Vivekananda M. ; et al.	2004-07-29
Imidazolyl derivatives as corticotropin releasing factor inhibitors App 20020183375 - Dubowchik, Gene M. ; et al.	2002-12-05
Neurotrophic difluoroamide agents Grant 6,096,762 - Vrudhula , et al. August 1, 2	2000-08-01
Cleavable conjugates for the delivery and release of agents in native form Grant 5,563,250 - Hylarides , et al. October 8, 1	1996-10-08
Chemically defined polymeric carriers for release of covalently linked agents Grant 5,549,883 - Srinivasan , et al. August 27, 1	1996-08-27
Targeting substance-diagnostic/therapeutic agent conjugates having schiff base linkages and methods for their preparation Grant 5,521,290 - Sivam , et al. May 28, 1	1996-05-28
Methods for isolating compounds using cleavable linker bound matrices Grant 5,141,648 - Hylarides , et al. August 25, 1	1992-08-25
Method of enhancing the effect of cytotoxic agents Grant 5,112,954 - Abrams , et al. May 12, 1	1992-05-12
Targeting substance-diagnostic/therapeutic agent conjugates having Schiff base linkages Grant 5,066,789 - Srinivasan , et al. November 19, 1	1991-11-19
Methods for introducing a sulfhydryl amino or hydroxyl groups to a compound Grant 5,017,693 - Hylarides , et al. May 21, 1	1991-05-21

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.